One of iHub's Most-Read Tickers: What's Really Going On With EMED
The Form 15: Electromedical Technologies filed Form 15-12g with the SEC on July 14, 2025, suspending 10-K/10-Q filings to focus resources on a restructuring. It did not go dark. EMED still discloses on OTC Markets' OTCID Basic Market tier.
The cleanup: In August 2025 the Company retired its largest convertible noteholder position and opened settlement talks with the remaining noteholders.
The catalyst: A real, company-confirmed joint venture with Lionheart Health, pairing EMED's bioelectronic devices with Lionheart's 500+ patent claims in wound healing.
Real Product + Restructuring Progress + A Confirmed JV = A Trade Setup Worth Watching
Photo: electromedtech.com
$EMED - What the Form 15 and the Lionheart Health Deal Actually Mean
Price: ~$0.0001 | Market Cap: ~$85K-$750K (varies by source) | Shares Out: 3.5B-3.73B
electromedtech.com | OTC Markets: EMED
Executive Summary
- What EMED is: Electromedical Technologies, Inc., a Scottsdale, AZ bioelectronics manufacturer making the WellnessPro line of prescription pain-therapy devices, on the market since 2002.
- The Form 15 event: Filed Form 15-12g with the SEC on July 14, 2025, suspending SEC reporting (no more 10-K/10-Q filings) as part of a stated restructuring.
- OTCID, not "dark": EMED still discloses on OTC Markets' OTCID Basic Market tier, with quarterly/annual financials and management certification filed through OTCIQ, separate from SEC EDGAR.
- Restructuring progress: An August 2025 release confirmed EMED retired its largest convertible noteholder position and opened settlement talks with the rest, aimed at reducing dilution.
- The Lionheart Health angle: A March 2025 joint venture is real and company-confirmed. A roll-up/"free equity" theory on message boards is not confirmed and is flagged as speculation below.
- Key risk: Extreme historical dilution (roughly 22 million shares in 2020 to billions by 2026) and inconsistent, unaudited post-2024 data. This is a speculative micro-cap trade setup, not a fundamentals-driven investment.
What Electromedical Technologies Actually Makes
Electromedical Technologies (OTCID: EMED) is a Scottsdale, Arizona bioelectronics manufacturer that has sold prescription pain-therapy devices since 2002. Its WellnessPro line uses microcurrent and interferential electrical stimulation to treat chronic pain:
- WellnessPro Plus - the original clinic/home unit
- WellnessPro POD - compact wearable
- WellnessPro Infinity - the newest flagship
- Wellness ION Pen - cold-laser device
The Company is small, about six employees, and has historically sold through independent distributors and clinical/chiropractic customers rather than retail.
Not a shell: a decades-old product line, real (if declining) revenue, a website and a named CEO
THE TRADE SETUP: A Real Product, a Real JV, and a Cap Table Under Repair
EMED has become one of the most heavily discussed tickers on iHub, driven by a mix of real news and speculation. The real part: the Form 15 to cut SEC reporting costs during a restructuring, the retired convertible noteholder, continued OTCID disclosure, and a genuine March 2025 JV with Lionheart Health. The speculative part: forum posts theorizing the JV rolls into Lionheart ahead of an IPO, handing EMED holders "free" equity. Neither company has confirmed that.
Recent Price
~$0.0001
Approximate
Market Cap
$85K-$750K
Varies by source
Disclosure Tier
OTCID
Basic Market
SEC Form 15
Jul 2025
Filed Jul 14, 2025
Lionheart JV
Mar 2025
Company-confirmed
Shares Out.
3.5B-3.73B
2026 snapshots
A classic high-risk bounce/momentum setup, not a value investment
THE LIONHEART HEALTH JOINT VENTURE: Fact vs. Forum Speculation
March 2025: The Confirmed Deal
Electromedical Technologies and Lionheart Health announced a joint venture for accelerated wound healing, combining EMED's bioelectronic device technology with Lionheart's portfolio of 500+ patent claims covering bioelectric protein expressions tied to tissue regeneration.
CEO Matthew Wolfson: "By integrating Lionheart Health's patented bioelectric accelerated healing protein expressions and our first in class device technology, we have created the ultimate accelerated wound healing solution."
Confirmed by the Companies:
- JV announced March 2025
- 500+ Lionheart patent claims
- Wound-healing focus
- CEO quote in the joint release
NOT Confirmed (Message Boards):
- "Roll-up" into Lionheart
- "Free bonus equity" for EMED holders
- Lionheart IPO timeline
- Valuation multiples ("Per AI")
The JV is real. The roll-up is retail speculation, not the basis for any price target here.
Source: Electromedical Technologies / Lionheart Health joint press release (Mar 2025), electromedtech.com. Roll-up/equity speculation comes from unverified iHub posts, not company filings.
THE RESTRUCTURING: What Form 15 Actually Changed
July 14, 2025 - Form 15-12g Filed
EMED suspended its obligation to file 10-Ks and 10-Qs. The Company's release framed it as a way "to focus internal resources during this restructuring phase," not a move to stop operating or stop disclosing.
August 6, 2025 - Mid-Year Restructuring Update
EMED "finalized an agreement with its largest convertible noteholder to retire their position, thereby reducing potential dilution and streamlining the cap table," and "initiated settlement discussions with remaining noteholders."
What's Still Open
The remaining noteholder settlements haven't been reported as concluded. A referenced Q1 2026 filing reportedly shows about $514,000 in separate noteholder debt still outstanding (per a secondary iHub reference, not pulled from a primary filing).
Source: EMED Form 15-12g (Jul 14, 2025), company press release via Newswire.com/ACCESS Newswire (Aug 6, 2025), OTC Markets OTCID tier documentation.
CLEANING UP THE CAP TABLE: Where Things Stand
Retiring the largest convertible noteholder is the single biggest lever a company has to slow dilution, because convertible notes are what drive ongoing share issuance at falling prices. Revenue has come down from FY2023 (~$1.35M) during the restructuring, alongside annual net losses since 2020.
Largest Noteholder
Retired
Aug 2025
Other Noteholders
In Progress
Settlement talks
FY2024 Revenue
$588.4K
Down 56% from FY2023
Disclosure
OTCID
Ongoing
Excluded From This Report
A "B. Riley initiates Buy, $38 price target" headline shows up in some EMED-tagged news feeds because of aggregator mix-ups with a similarly named but unrelated company, Electromed, Inc. (NYSE American: ELMD). That headline belongs to ELMD, not EMED.
PLACEHOLDER / UNCONFIRMED -- post-2024 figures come from third-party aggregators rather than a primary OTCIQ filing pulled for this report. Cross-check against the current disclosure before relying on them.
Valuation Snapshot
Share Price
~$0.0001
PLACEHOLDER -- confirm current quote before publishing
Shares Outstanding
3.5B-3.73B
Inconsistent across sources/dates
Market Cap
$85K-$750K
Wide range depending on vendor
52-Week Range
$0.000001 - $0.0018
Extremely wide; post-dilution price swings
FY2024 Revenue
$588.4K
Down 56% from FY2023's $1.35M
Q2 2025 Revenue
$7.15K
Last SEC-reported quarter before Form 15
PLACEHOLDER / UNCONFIRMED -- these figures come from third-party aggregators and vary meaningfully between sources, a common issue with heavily diluted, deregistered micro-caps. Pull the current OTCIQ-filed disclosure for exact numbers.
Company Overview
- History: Founded 2002, headquartered at 16413 N 91st Street, Unit C140, Scottsdale, AZ 85260. Trades OTC as EMED.
- Core products: WellnessPro Plus, WellnessPro POD and WellnessPro Infinity bioelectronic pain-therapy devices, plus the Wellness ION Pen cold laser.
- Business model: Manufacturer and distributor of prescription and consumer bioelectronic therapy devices through independent distributors and clinical channels.
- Headcount: About six employees.
- Contact: 1 (888) 880-7888; info@electromedtech.com
CHIEF EXECUTIVE OFFICER:
Matthew N. Wolfson
- Public face of the Company's restructuring and the Lionheart Health joint venture
- Quoted directly in both the March 2025 JV announcement and the August 2025 restructuring update
PLACEHOLDER / PARTIAL ROSTER -- Wolfson is the only officer independently confirmed for this report. An icon is used because no confirmed photo was sourced. Confirm a fuller roster from OTCIQ disclosure if a complete board listing is wanted.
Recent Milestones
What Traders Should Know
✓ Real product, real history: An actual bioelectronic device line on the market since 2002, a named CEO and an active restructuring plan.
✓ Still disclosing: OTCID status means EMED keeps filing financials with OTC Markets. Check the latest OTCIQ filing for the freshest numbers.
✓ Lionheart JV is the upside catalyst: Any further news on the partnership, or the roll-up chatter resolving one way or the other, is likely to move the stock.
⚠ Share count is the thing to watch: Historical dilution has been significant, so position sizing and trading volume matter more here than with a typical stock.
⚠ Data varies by source: With SEC filings suspended, figures differ by vendor. Cross-check against the current OTCIQ disclosure before acting.
The Bottom Line: Why EMED Deserves a Spot on Your Watch List
Electromedical Technologies (OTCID: EMED) brings something many message-board favorites don't have: a real, decades-old product line, a confirmed and named CEO, active progress on cleaning up its cap table, and a genuine joint venture with Lionheart Health that gives it a real shot at upside if that partnership keeps developing.
The Form 15 looks alarming at first glance, but it's a restructuring move, not an information blackout. EMED keeps disclosing through OTCID. The Lionheart roll-up buzz is worth watching, but it's unconfirmed speculation, not company guidance, and shouldn't be anyone's sole reason for taking a position.
Between the retired noteholder debt, the ongoing settlement talks and the Lionheart relationship, there's a credible case for renewed interest, balanced against heavy historical dilution that means any rally invites real overhead supply.
A trade setup built on real news flow, not a fundamentals-driven long-term hold
Key Resources & Contacts
Company Website: electromedtech.com
OTC Markets Profile: OTC Markets: EMED
Lionheart Health: lionhearthealth.com
Company Headquarters: 16413 N 91st Street, Unit C140, Scottsdale, AZ 85260 | 1 (888) 880-7888 | info@electromedtech.com
Liked This Report?
DDAmanda tracks 100+ stocks like this one, with AI-powered dilution alerts, daily scans, and research just like what you just read.
See What Else We're Tracking →Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. It is not to be considered as an offer to buy or sell securities of any type. Electromedical Technologies, Inc. filed Form 15-12g with the SEC on July 14, 2025 and no longer files periodic reports (10-K/10-Q) with the SEC; it continues to disclose financial information through OTC Markets' OTCID Basic Market tier, which is a separate, less comprehensive disclosure regime than SEC reporting. The Company's share count has grown substantially over time and further dilution remains possible. Financial figures in this report are drawn from third-party aggregators and company press releases rather than audited SEC filings and should be independently verified before use. The Lionheart Health joint venture referenced in this report is confirmed by both companies; any theory involving a future roll-up, IPO, or equity distribution connected to that joint venture is unconfirmed message-board speculation, not company disclosure, and is not represented here as fact or as an investment thesis. This is a highly speculative, low-priced OTC security carrying significant risk of substantial or total loss. This report is compiled from public sources including company press releases, OTC Markets disclosures, and electromedtech.com; DDAmanda has not independently verified all company statements or characterizations. Always do your own due diligence and consult with a licensed financial advisor before making investment decisions. Data current as of September 26, 2026.